Orthofix Medical (NASDAQ:OFIX) Receives "Sell (D-)" Rating from Weiss Ratings

Key Points

• Orthofix Medical has been reaffirmed a "sell (D-)" rating by Weiss Ratings, amidst mixed reviews from other analysts showing a range of ratings from "buy" to "hold."
• Despite an average target price of $21.75, the company reported a loss of ($0.36) earnings per share, significantly missing the consensus estimate.
• Institutional investors dominate ownership, holding approximately 89.76% of Orthofix Medical's stock, indicating strong interest from large players in the market.

Orthofix Medical (NASDAQ:OFIX - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities researchers at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Other equities research analysts have also issued research reports about the stock. Wall Street Zen upgraded shares of Orthofix Medical from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. Barrington Research reaffirmed an "outperform" rating and set a $17.00 price objective on shares of Orthofix Medical in a research report on Tuesday, September 23rd. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Orthofix Medical presently has an average rating of "Moderate Buy" and an average price target of $21.75.

Orthofix Medical Stock Up 1.2%

Shares of OFIX opened at $14.37 on Wednesday. The firm has a market cap of $567.47 million, a PE ratio of -4.53 and a beta of 0.89. The company's fifty day moving average is $14.16 and its two-hundred day moving average is $12.98. Orthofix Medical has a fifty-two week low of $10.24 and a fifty-two week high of $20.73. The company has a quick ratio of 1.50, a current ratio of 2.67 and a debt-to-equity ratio of 0.38.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last posted its earnings results on Tuesday, August 5th. The medical device company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.40). Orthofix Medical had a negative net margin of 15.29% and a negative return on equity of 25.43%. The business had revenue of $203.12 million for the quarter, compared to analyst estimates of $196.89 million. Orthofix Medical has set its FY 2025 guidance at EPS. Analysts forecast that Orthofix Medical will post -2.81 earnings per share for the current year.

Institutional Investors Weigh In On Orthofix Medical

Large investors have recently made changes to their positions in the company. US Bancorp DE raised its holdings in shares of Orthofix Medical by 684.6% during the first quarter. US Bancorp DE now owns 5,673 shares of the medical device company's stock valued at $93,000 after acquiring an additional 4,950 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Orthofix Medical during the 2nd quarter worth $147,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its stake in shares of Orthofix Medical by 32.6% during the 2nd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 13,297 shares of the medical device company's stock worth $148,000 after purchasing an additional 3,271 shares during the last quarter. Strs Ohio acquired a new position in Orthofix Medical in the 1st quarter valued at $150,000. Finally, The Manufacturers Life Insurance Company grew its stake in Orthofix Medical by 21.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 14,867 shares of the medical device company's stock valued at $166,000 after buying an additional 2,589 shares during the last quarter. Institutional investors and hedge funds own 89.76% of the company's stock.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.